ArticleWorld journal of hepatology2017
Advanced non-alcoholic steatohepatitis cirrhosis: A high-risk population for pre-liver transplant portal vein thrombosis.
Article in World journal of hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Prevalence of portal vein thrombosis in non-alcoholic fatty liver disease: a meta-analysis of observational studies.Journal of thrombosis and thrombolysis · 2024Pooled it
- Metabolic Disorders and Risk of Portal Vein Thrombosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022Pooled it
- NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH.Hepatology (Baltimore, Md.) · 2022Trial
- Management of Nonmalignant Portal Vein Thrombosis in Cirrhosis.GE Portuguese journal of gastroenterology · 2024Review
- The Yin and the Yang of Hemostasis in End-Stage Liver Disease.Journal of clinical medicine · 2023Review
- Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV).Wiener klinische Wochenschrift · 2023Article
- Article
- Portal vein thrombosis risk factors in liver transplant candidates.Hepatology forum · 2022Article
- Coagulation and Endothelial Dysfunction Associated with NAFLD: Current Status and Therapeutic Implications.Journal of clinical and translational hepatology · 2022Review
- Direct oral anticoagulant administration in cirrhotic patients with portal vein thrombosis: What is the evidence?World journal of hepatology · 2022Review
- Pre-transplant portal vein thrombosis in non-alcoholic fatty liver disease patients-pathogenesis, risk factors, and implications on management.Translational gastroenterology and hepatology · 2022Review
- Incident portal vein thrombosis in liver transplant recipients in New Zealand: Predictors of risk and validation of portal vein thrombosis risk index calculator.Frontiers in transplantation · 2022Article
- Portal vein thrombosis: A concise review (Review).Experimental and therapeutic medicine · 2021Review
- Plasminogen activator inhibitor is significantly elevated in liver transplant recipients with decompensated NASH cirrhosis.BMJ open gastroenterology · 2021Article
- Nontumoral Portal Vein Thrombosis: A Challenging Consequence of Liver Cirrhosis.Journal of clinical and translational hepatology · 2020Review
- Nonalcoholic steatohepatitis Fitness Intervention in Thrombosis (NASHFit): Study protocol for a randomized controlled trial of a supervised aerobic exercise program to reduce elevated clotting risk in patients with NASH.Contemporary clinical trials communications · 2020Article
- Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative Review.Advances in therapy · 2020Review
- Nonalcoholic Fatty Liver Disease-Evidence for a Thrombophilic State?Current pharmaceutical design · 2020Review
- Development of a Model to Predict Portal Vein Thrombosis in Liver Transplant Candidates: The Portal Vein Thrombosis Risk Index.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2019Article
- Portal vein thrombosis in cirrhosis: Why a well-known complication is still matter of debate.World journal of gastroenterology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo examine if liver transplant recipients with high-risk non-alcoholic steatohepatitis (NASH) are at increased risk for pre-transplant portal venous thrombosis.
methodsData on all liver transplants in the United States from February 2002 through September 2014 were analyzed. Recipients were sorted into three distinct groups: High-risk (age > 60, body mass index > 30 kg/m
resultsThirty-five thousand and seventy-two candidates underwent liver transplantation and of those organ recipients, 465 were transplanted for high-risk and 2775 for low-risk NASH. Two thousand six hundred and twenty-six (7.5%) recipients had pre-transplant portal vein thrombosis; 66 (14.2%) of the high-risk NASH group had portal vein thrombosis
conclusionLiver transplant candidates with high-risk NASH are at the greatest risk for portal vein thrombosis development prior to transplantation. These candidates may benefit from interventions to decrease their likelihood of clot formation and resultant downstream hepatic decompensating events. Prospective study is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.